A Phase 2 interventional study of Olaparib and Placebo in Metastatic Castration-resistant Prostate Cancer, sponsored by AstraZeneca. Completed at 41 sites in 11 countries. Open to male participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-11-14.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing olaparib in Prostatic Neoplasms — 2 open to participants now, 11 under way, 2 of them phase 3. olaparib · Prostatic Neoplasms.
Among the 25 studies testing olaparib in Prostatic Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2014, is one of 14 in phase 2, and was the 1st registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →2 of the 25 studies testing olaparib in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Zin W Myint · Sites in United States
Ages 18+ · Men only
VA Office of Research and Development · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 130 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 4 · Phase 4 1
First in 2014; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 158 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 43 across the 25 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 25 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
91 studies in Prostatic Neoplasms by AstraZeneca: 15 open now, 29 under way, 8 of them phase 3. Of 58 finished, 11 (19%) have results posted.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 22nd largest by enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2014, is one of 16 in phase 2, and was the 41st registered.
AstraZeneca’s Prostatic Neoplasms studies by the year they started, since 1994.
2 of the studies testing olaparib in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04038502VA Office of Research and DevelopmentCarboplatin or Olaparib for BRcA Deficient Prostate Cancer | 2027-08-31 |
| NCT02861573Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | 2027-10-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies testing olaparib in Prostatic Neoplasms, from their registry updates:
Among AstraZeneca’s 91 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and pharmacokinetics (PK) of olaparib when given in addition to abiraterone 1000 mg once daily. Part B is a randomised, double-blind, placebo controlled comparison of the efficacy, safety and tolerability of the dose of olaparib selected from Part A when given in addition to abiraterone, versus placebo given in addition to abiraterone. Abiraterone is indicated in combination with prednisone or prednisolone for the treatment of patients with metastatic CRPC. Prednisone or prednisolone 5 mg twice daily (bid) will be administered with the abiraterone in this study.
This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and PK of olaparib when given in addition to abiraterone 1000 mg once daily. Part B is a randomised, double-blind, placebo-controlled comparison of the efficacy, safety and tolerability of the dose of olaparib selected from Part A when given in addition to abiraterone, versus placebo in addition to abiraterone.
Abiraterone is indicated in combination with prednisone or prednisolone for the treatment of patients with metastatic CRPC. Prednisone or prednisolone 5 mg bid will be administered with the abiraterone in this study, but throughout this protocol the treatment will be referred to simply as abiraterone.
For Part A of the study, 15 to 18 evaluable patients (Cohorts 1 and 2) are planned to be enrolled from approximately 4 sites in approximately 1 or 2 countries, and a further 12 patients may be recruited into a 3rd cohort if necessary.
For Part B of the study, approximately 140 patients who have received prior chemotherapy containing docetaxel will be randomised from approximately 40 sites in North America and Europe. Patients who have been dosed in Part A of the study may not participate in Part B.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Provide informed consent for the pharmacogenetic sampling and analyses.
Exclusion Criteria:
Treatment with any of the following:
Any of the following cardiac criteria:
Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
Exclusion from the genetic research may be for any of the exclusion criteria specified in the main study or any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200 mg or 300 mg bid
Drug: Olaparib · Drug: Abiraterone · Drug: Prednisone or prednisolone
placebo to match olaparib bid
Drug: Placebo · Drug: Abiraterone · Drug: Prednisone or prednisolone
Olaparib bid
Also known as: PARP inhibition
Placebo bid
Also known as: Placebo to PARP inhibition
Abiraterone 1000 mg
Drug pages: Prednisone · Prednisolone
Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.
Part A: Percentage of Patients Experiencing Adverse Events (AEs)
The safety and tolerability of olaparib in combination with abiraterone was assessed during Part A of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented. Severity of AEs was assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events (CTCAE) v4.0. AEs were assigned to a Grade from 1 through 5 as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. 'c-r' = causally related 'discont' = discontinuation.
Time frame: Cohort 1 and 2: From baseline in Part A (Day 1 for each cohort) up to 30 days following last dose of study treatment.
Part A: Number of Patients With Dose Limiting Toxicities (DLTs)
DLTs were assessed by a Safety Review Committee (SRC) after a minimum of 3 patients had received at least 14 days of treatment in Part A. A DLT was defined as any toxicity which was not a recognised AE of abiraterone or prednisolone, and was not attributable to the disease or disease-related processes under investigation, which occurred during a minimum period of 14 days treatment and which included: 1. haematological toxicity CTCAE v4.0 Grade 4 or higher present for more than 4 days (except anaemia); 2. non-haematological toxicity CTCAE v4.0 Grade 3 or higher including infection, corrected QT interval prolongation; 3. any other toxicity that was greater than that at baseline, was clinically significant and/or unacceptable, did not respond to supportive care, resulted in a disruption of dosing schedule of 7 days or more, or was judged to be a DLT by the SRC. A DLT excluded alopecia and isolated laboratory changes of any grade without clinical sequelae or clinical significance.
Time frame: From Day 1 for Cohort 1 and from Day 4 for Cohort 2 up to 14 days treatment with olaparib + abiraterone for 3 patients.
Part B: Median Radiological Progression-Free Survival (rPFS) Time
The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (for soft tissue disease) and Prostate Cancer Working Group 2 (PCWG-2) (for bone disease) criteria, or death. Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion. Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit).
Time frame: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.
Part B: Percentage of Patients With Progression Events or Death (rPFS)
The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using RECIST version 1.1 (for soft tissue disease) and PCWG-2 (for bone disease) criteria, or death. Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion. Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit). The percentage of patients with progression events is presented overall and according to RECIST 1.1 and/or PCWG-2 criteria, or death.
Time frame: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.
Part A Pharmacokinetics (PK): Olaparib Maximum Plasma Concentration at Steady State (Cmax,ss)
Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Part A PK: Abiraterone Cmax,ss
Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Part A PK Analysis: Olaparib Time to Reach Maximum Plasma Concentration at Steady State (Tmax,ss)
Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib tmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Part A PK: Abiraterone Tmax,ss
Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone tmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Part A PK Analysis: Olaparib Minimum Plasma Concentration at Steady State (Cmin,ss)
Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmin,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Part A PK: Abiraterone Cmin,ss
Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmin,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Part A PK Analysis: Olaparib Area Under the Plasma Concentration-Time Curve at Steady State (AUCss)
Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib AUCss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Part A PK: Abiraterone AUCss
Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone AUCss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Part B: Percentage of Patients Experiencing AEs
The safety and tolerability of olaparib when given in combination with abiraterone was assessed during Part B of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented. Severity of AEs was assessed using the NCI Common Terminology CTCAE v4.0. AEs were assigned to a Grade from 1 through 5 as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. 'c-r' = causally related. 'discont' = discontinuation. 'ola/pla' = olaparib/placebo.
Time frame: From first dose of study treatment following randomisation in Part B up to 30 days following last dose of study treatment (up to approximately 3 years).
Part B: Median Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Levels
The best percentage change from baseline in PSA levels was determined to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone. The best percentage change was defined as the biggest reduction in PSA level compared with baseline or smallest increase in the absence of a decrease.
Time frame: From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.
Part B: Percentage of Patients With PSA Responses
The percentages of patients with single visit responses and with confirmed responses are presented to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone. A single visit response was defined as any post-dose visit PSA level reduced by 50% or more compared with baseline. A confirmed response was defined as a reduction in PSA level of 50% or more on 2 consecutive occasions at least 4 weeks apart compared with baseline. Patients may have had more than 1 single visit response or confirmed response but were counted once.
Time frame: From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.
Part B: Median Best Percentage Change From Baseline in Circulating Tumour Cell (CTC) Level
The median best percentage change from baseline in CTC levels was determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone. The best percentage change was defined as the biggest CTC level reduction compared with baseline or smallest increase in the absence of a decrease.
Time frame: From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.
Part B: Percentage of Patients With at Least One Objective Response (Objective Response Rate [ORR])
The overall radiological ORR was calculated to assess the anti-tumour activity of olaparib in combination with abiraterone, compared with placebo in combination with abiraterone. The best overall ORR was defined as the percentage of patients with at least 1 visit response of complete response (CR) or partial response (PR) in soft tissue disease assessed by RECIST 1.1 and also bone scan status of non-progressive disease or non-evaluable for their bone scans assessed by PCWG-2. CR: Disappearance of all target lesions. Reduction of pathological lymph nodes to \<10 millimetres. PR: At least a 30% decrease in the sum of diameters of target lesions from baseline. The percentage of patients with a response is presented.
Time frame: From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.
Median Time to First Subsequent Therapy (TFST) and Median Time to Second Subsequent Therapy (TSST)
The TFST and TSST were determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone. TFST was defined as the time from randomisation to the earlier of first subsequent anti-cancer therapy start date following study treatment discontinuation, or death. TSST was defined as the time from randomisation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death.
Time frame: From randomisation until analysis cut-off date (up to approximately 3 years).
Part B: Median Overall Survival (OS)
OS was determined to assess the efficacy of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone. OS was performed at the time of the analysis of rPFS, and the median OS, calculated using the Kaplan-Meier technique, is presented.
Time frame: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.
Part B: Median Time to Second Progression or Death (PFS2)
The efficacy of olaparib when given in combination with abiraterone was assessed by PFS2, defined by local standard clinical practice and included objective radiological progression by RECIST 1.1 (soft tissue), symptomatic progression, rise in PSA level or death in the absence of overall progression.
Time frame: From randomisation until analysis cut-off date (up to approximately 3 years).
In this 2-part study, patients with metastatic castrate-resistant prostate cancer (mCRPC) were recruited at 41 sites in Europe, Russia and North America. Part A had 2 cohorts for olaparib dose selection when given with approved treatment abiraterone. Part B compared olaparib versus placebo both with abiraterone in post-chemotherapy mCRPC patients.
| Milestone | Part A Cohort 1: Olaparib 200 mg + Abiraterone | Part A Cohort 2: Olaparib 300 mg + Abiraterone | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone |
|---|---|---|---|---|
| Started | 3 | 13 | 0 | 0 |
| Completed | 2 | 1 | 0 | 0 |
| Not completed | 1 | 12 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Condition under investigation worsened | 1 | 9 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| Milestone | Part A Cohort 1: Olaparib 200 mg + Abiraterone | Part A Cohort 2: Olaparib 300 mg + Abiraterone | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone |
|---|---|---|---|---|
| Started | 0 | 0 | 71 | 71 |
| Received olaparib/placebo | 0 | 0 | 71 | 71 |
| Received abiraterone | 0 | 0 | 71 | 71 |
| Completed | 0 | 0 | 25 | 24 |
| Not completed | 0 | 0 | 46 | 47 |
| Withdrew: Death | 0 | 0 | 43 | 44 |
| Withdrew: Reason not recorded | 0 | 0 | 1 | 0 |
| Withdrew: Screen failure | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
The safety and tolerability of olaparib in combination with abiraterone was assessed during Part A of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented. Severity of AEs was assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events (CTCAE) v4.0. AEs were assigned to a Grade from 1 through 5 as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. 'c-r' = causally related 'discont' = discontinuation.
| Percentage of patients | Part A Cohort 1: Olaparib 200 mg + Abiraterone | Part A Cohort 2: Olaparib 300 mg + Abiraterone |
|---|---|---|
| Any AE c-r to olaparib + abiraterone | 66.7 | 46.2 |
| Any AE c-r to olaparib only | 33.3 | 7.7 |
| Any AE c-r to abiraterone only | 0 | 15.4 |
| Any AE CTCAE Grade 3 or higher | 66.7 | 23.1 |
| Any AE CTCAE Grade 3 or higher c-r to olaparib | 0 | 7.7 |
| Any AE CTCAE Grade 3 or higher c-r to abiraterone | 0 | 7.7 |
| Any AE with outcome = death | 0 | 0 |
| Any serious AE (SAE) | 66.7 | 23.1 |
| Any SAE c-r to olaparib | 0 | 0 |
| Any SAE c-r to abiraterone | 0 | 0 |
| Any AE causing discont of olaparib | 0 | 7.7 |
| Any AE causing discont of olaparib c-r to olaparib | 0 | 0 |
| Any AE causing discont olaparib c-r to abiraterone | 0 | 0 |
DLTs were assessed by a Safety Review Committee (SRC) after a minimum of 3 patients had received at least 14 days of treatment in Part A. A DLT was defined as any toxicity which was not a recognised AE of abiraterone or prednisolone, and was not attributable to the disease or disease-related processes under investigation, which occurred during a minimum period of 14 days treatment and which included: 1. haematological toxicity CTCAE v4.0 Grade 4 or higher present for more than 4 days (except anaemia); 2. non-haematological toxicity CTCAE v4.0 Grade 3 or higher including infection, corrected QT interval prolongation; 3. any other toxicity that was greater than that at baseline, was clinically significant and/or unacceptable, did not respond to supportive care, resulted in a disruption of dosing schedule of 7 days or more, or was judged to be a DLT by the SRC. A DLT excluded alopecia and isolated laboratory changes of any grade without clinical sequelae or clinical significance.
| Patients | Part A Cohort 1: Olaparib 200 mg + Abiraterone | Part A Cohort 2: Olaparib 300 mg + Abiraterone |
|---|---|---|
| Part A: Number of Patients With Dose Limiting Toxicities (DLTs) | 2 | 4 |
The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (for soft tissue disease) and Prostate Cancer Working Group 2 (PCWG-2) (for bone disease) criteria, or death. Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion. Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit).
| Months | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone |
|---|---|---|
| Part B: Median Radiological Progression-Free Survival (rPFS) Time | 13.8 (10.8 to 20.4) | 8.2 (5.5 to 9.7) |
The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using RECIST version 1.1 (for soft tissue disease) and PCWG-2 (for bone disease) criteria, or death. Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion. Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit). The percentage of patients with progression events is presented overall and according to RECIST 1.1 and/or PCWG-2 criteria, or death.
| Percentage of patients | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone |
|---|---|---|
| Part B: Percentage of Patients With Progression Events or Death (rPFS) | 64.8 | 76.1 |
Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
| micrograms per millilitre (mcg/mL) | Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone |
|---|---|---|
| Olaparib alone | 7.781 ± 25.06 | — |
| Olaparib + abiraterone | 6.504 ± 20.90 | 7.724 ± 28.05 |
Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
| nanograms per millilitre (ng/mL) | Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone |
|---|---|---|
| Abiraterone alone | — | 145.8 ± 135.5 |
| Olaparib + abiraterone | 130.7 ± 68.87 | 86.12 ± 48.88 |
Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib tmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
| Hours (h) | Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone |
|---|---|---|
| Olaparib alone | 2.000 (1.00 to 2.17) | — |
| Olaparib + abiraterone | 2.080 (2.00 to 4.00) | 2.000 (0.500 to 3.02) |
Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone tmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
| Hours | Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone |
|---|---|---|
| Abiraterone alone | — | 2.525 (1.00 to 3.00) |
| Olaparib + abiraterone | 3.000 (1.08 to 3.00) | 2.500 (2.00 to 3.02) |
Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmin,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
| mcg/mL | Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone |
|---|---|---|
| Olaparib alone | 1.264 ± 46.58 | — |
| Olaparib + abiraterone | 0.9170 ± 31.56 | 1.279 ± 65.36 |
Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmin,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
| ng/mL | Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone |
|---|---|---|
| Abiraterone alone | — | 8.376 ± 96.52 |
| Olaparib + abiraterone | 7.983 ± 163.3 | 6.358 ± 50.96 |
Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib AUCss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
| mcg*h/mL | Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone |
|---|---|---|
| Olaparib alone | 45.27 ± 31.89 | — |
| Olaparib + abiraterone | 40.83 ± 11.47 | 49.51 ± 37.30 |
Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone AUCss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.
| ng*h/mL | Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone |
|---|---|---|
| Abiraterone alone | — | 825.5 ± 105.5 |
| Olaparib + abiraterone | 718.9 ± 102.0 | 524.6 ± 37.65 |
The safety and tolerability of olaparib when given in combination with abiraterone was assessed during Part B of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented. Severity of AEs was assessed using the NCI Common Terminology CTCAE v4.0. AEs were assigned to a Grade from 1 through 5 as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. 'c-r' = causally related. 'discont' = discontinuation. 'ola/pla' = olaparib/placebo.
| Percentage of patients | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone |
|---|---|---|
| Any AE c-r to ola/pla + abiraterone | 45.1 | 12.7 |
| Any AE c-r to ola/pla only | 18.3 | 9.9 |
| Any AE c-r to abiraterone only | 1.4 | 7.0 |
| Any AE CTCAE Grade 3 or higher | 53.5 | 28.2 |
| Any AE CTCAE Grade 3 or higher c-r to ola/pla | 23.9 | 5.6 |
| Any AE CTCAE Grade 3 or higher c-r to abiraterone | 16.9 | 1.4 |
| Any AE with outcome = death | 5.6 | 1.4 |
| Any AE with outcome = death c-r to ola/pla | 1.4 | 0 |
| Any AE with outcome = death c-r to abiraterone | 0 | 0 |
| Any SAE | 35.2 | 19.7 |
| Any SAE c-r to ola/pla | 9.9 | 1.4 |
| Any SAE c-r to abiraterone | 5.6 | 0 |
| Any AE causing discont of ola/pla | 29.6 | 9.9 |
| Any AE causing discont of treatment c-r to ola/pla | 16.9 | 5.6 |
| Any AE causing discont treatment c-r abiraterone | 8.5 | 1.4 |
The best percentage change from baseline in PSA levels was determined to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone. The best percentage change was defined as the biggest reduction in PSA level compared with baseline or smallest increase in the absence of a decrease.
| Percentage change in PSA level | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone |
|---|---|---|
| Part B: Median Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Levels | -54.16 (-100.0 to 533.2) | -49.85 (-100.0 to 230.1) |
The percentages of patients with single visit responses and with confirmed responses are presented to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone. A single visit response was defined as any post-dose visit PSA level reduced by 50% or more compared with baseline. A confirmed response was defined as a reduction in PSA level of 50% or more on 2 consecutive occasions at least 4 weeks apart compared with baseline. Patients may have had more than 1 single visit response or confirmed response but were counted once.
| Percentage of patients | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone |
|---|---|---|
| Single visit response | 50.7 (43.10 to 58.31) | 47.9 (40.29 to 55.49) |
| Confirmed response | 47.9 (40.29 to 55.49) | 42.3 (34.74 to 49.77) |
The median best percentage change from baseline in CTC levels was determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone. The best percentage change was defined as the biggest CTC level reduction compared with baseline or smallest increase in the absence of a decrease.
| Percentage change in CTC level | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone |
|---|---|---|
| Part B: Median Best Percentage Change From Baseline in Circulating Tumour Cell (CTC) Level | -1.0 (-478 to 613) | -1.0 (-1279 to 414) |
The overall radiological ORR was calculated to assess the anti-tumour activity of olaparib in combination with abiraterone, compared with placebo in combination with abiraterone. The best overall ORR was defined as the percentage of patients with at least 1 visit response of complete response (CR) or partial response (PR) in soft tissue disease assessed by RECIST 1.1 and also bone scan status of non-progressive disease or non-evaluable for their bone scans assessed by PCWG-2. CR: Disappearance of all target lesions. Reduction of pathological lymph nodes to \<10 millimetres. PR: At least a 30% decrease in the sum of diameters of target lesions from baseline. The percentage of patients with a response is presented.
| Percentage of patients | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone |
|---|---|---|
| Part B: Percentage of Patients With at Least One Objective Response (Objective Response Rate [ORR]) | 27.3 | 31.6 |
The TFST and TSST were determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone. TFST was defined as the time from randomisation to the earlier of first subsequent anti-cancer therapy start date following study treatment discontinuation, or death. TSST was defined as the time from randomisation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death.
| Months | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone |
|---|---|---|
| TFST | 13.5 (11.1 to 17.2) | 9.7 (7.3 to 12.9) |
| TSST | 19.6 (16.5 to 25.1) | 18.0 (16.9 to 20.6) |
OS was determined to assess the efficacy of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone. OS was performed at the time of the analysis of rPFS, and the median OS, calculated using the Kaplan-Meier technique, is presented.
| Months | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone |
|---|---|---|
| Part B: Median Overall Survival (OS) | 22.7 (17.4 to 29.4) | 20.9 (17.6 to 26.3) |
The efficacy of olaparib when given in combination with abiraterone was assessed by PFS2, defined by local standard clinical practice and included objective radiological progression by RECIST 1.1 (soft tissue), symptomatic progression, rise in PSA level or death in the absence of overall progression.
| Months | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone |
|---|---|---|
| Part B: Median Time to Second Progression or Death (PFS2) | 23.3 (17.4 to NA) | 18.5 (16.1 to 23.8) |
Collected over Part A: From baseline (Day 1 for each cohort) up to 30 days following last dose of study treatment. Part B: From first dose of study treatment following randomisation up to 30 days following last dose of study treatment (up to approximately 3 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Cohort 1: Olaparib 200 mg + Abiraterone | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Part A Cohort 2: Olaparib 300 mg + Abiraterone | 1/13 (7.7%) | 3/13 (23.1%) | 7/13 (53.8%) |
| Part B: Olaparib + Abiraterone | 43/71 (60.6%) | 25/71 (35.2%) | 63/71 (88.7%) |
| Part B: Placebo + Abiraterone | 45/71 (63.4%) | 14/71 (19.7%) | 52/71 (73.2%) |
| Event | Part A Cohort 1: Olaparib 200 mg + Abiraterone | Part A Cohort 2: Olaparib 300 mg + Abiraterone | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 1/3 | 0/13 | 0/71 | 0/71 |
| PneumoniaInfections and infestations | 1/3 | 0/13 | 4/71 | 3/71 |
| Urinary tract infectionInfections and infestations | 1/3 | 0/13 | 2/71 | 2/71 |
| Humerus fractureInjury, poisoning and procedural complications | 1/3 | 0/13 | 0/71 | 0/71 |
| Eye haemorrhageEye disorders | 0/3 | 1/13 | 0/71 | 0/71 |
| Intestinal obstructionGastrointestinal disorders | 0/3 | 1/13 | 0/71 | 0/71 |
| CellulitisInfections and infestations | 0/3 | 1/13 | 0/71 | 0/71 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/13 | 5/71 | 1/71 |
| Acute myocardial infarctionCardiac disorders | 0/3 | 0/13 | 2/71 | 0/71 |
| Myocardial infarctionCardiac disorders | 0/3 | 0/13 | 2/71 | 0/71 |
| Event | Part A Cohort 1: Olaparib 200 mg + Abiraterone | Part A Cohort 2: Olaparib 300 mg + Abiraterone | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone |
|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 3/3 | 1/13 | 17/71 | 14/71 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 3/13 | 11/71 | 8/71 |
| NauseaGastrointestinal disorders | 2/3 | 2/13 | 27/71 | 15/71 |
| Rectal haemorrhageGastrointestinal disorders | 2/3 | 0/13 | 1/71 | 0/71 |
| Lower respiratory tract infectionInfections and infestations | 2/3 | 0/13 | 0/71 | 3/71 |
| FallInjury, poisoning and procedural complications | 2/3 | 1/13 | 5/71 | 1/71 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 2/3 | 0/13 | 1/71 | 5/71 |
| Tympanic membrane perforationEar and labyrinth disorders | 1/3 | 0/13 | 0/71 | 0/71 |
| Ocular hyperaemiaEye disorders | 1/3 | 1/13 | 0/71 | 0/71 |
| Abdominal discomfortGastrointestinal disorders | 1/3 | 0/13 | 0/71 | 1/71 |
The Safety analysis set consisted of all patients who received at least 1 dose of study treatment in Part A and all patients randomised into Part B of the study who received at least 1 dose of study treatment.
| Age, Categorical(Participants) | Part A Cohort 1: Olaparib 200 mg + Abiraterone | Part A Cohort 2: Olaparib 300 mg + Abiraterone | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 3 | 17 | 22 | 42 |
| >=65 years | 3 | 10 | 54 | 49 | 116 |
| Sex: Female, Male(Participants) | Part A Cohort 1: Olaparib 200 mg + Abiraterone | Part A Cohort 2: Olaparib 300 mg + Abiraterone | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 3 | 13 | 71 | 71 | 158 |
| Ethnicity (NIH/OMB)(Participants) | Part A Cohort 1: Olaparib 200 mg + Abiraterone | Part A Cohort 2: Olaparib 300 mg + Abiraterone | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 11 | 5 | 17 |
| Not Hispanic or Latino | 2 | 13 | 58 | 63 | 136 |
| Unknown or Not Reported | 0 | 0 | 2 | 3 | 5 |
| Race (NIH/OMB)(Participants) | Part A Cohort 1: Olaparib 200 mg + Abiraterone | Part A Cohort 2: Olaparib 300 mg + Abiraterone | Part B: Olaparib + Abiraterone | Part B: Placebo + Abiraterone | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 | 2 |
| White | 3 | 13 | 67 | 67 | 150 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 2 | 3 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Apr 2014 to primary completion in Sep 2017, 41 months.
Results were first posted in Oct 2018, 1 year after primary completion.
Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 41 months is above that.
Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib